Cost effectiveness of crizotinib for anaplastic lymphoma kinase-positive, non-small-cell lung cancer: Who is going to blink at the cost?

Journal of Clinical Oncology

Volumn 32, Issue 10, 2014, Pages 983-985

  Kelly, Ronan J ^a   Smith, Thomas J ^a   Hillner, Bruce E ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CISPLATIN; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEMCITABINE; PEMETREXED; ANTINEOPLASTIC AGENT; EML4 ALK FUSION PROTEIN, HUMAN; EML4-ALK FUSION PROTEIN, HUMAN; ONCOPROTEIN; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; TUMOR MARKER;

CANCER CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DRUG COST; EDITORIAL; HEALTH STATUS; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; ECONOMICS; IMMUNOHISTOCHEMISTRY; LUNG TUMOR; NOTE;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; ONCOGENE PROTEINS, FUSION; PYRAZOLES; PYRIDINES; TUMOR MARKERS, BIOLOGICAL;

EID: 84901608386     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.54.6002     Document Type: Editorial

References (16)

1. Kris MG JB, Kwiatkowski DJ, et al: Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI's Lung Cancer Mutation Consortium (LCMC). J Clin Oncol 29:477s, 2011 (suppl; abstr CRA7506)
2. Soda M, Choi YL, Enomoto M, et al: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448:561-566, 2007 (Pubitemid 47206930)
3. Shaw AT, Yeap BY, Mino-Kenudson M, et al: Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 27:4247-4253, 2009
4. Kwak EL, Bang YJ, Camidge DR, et al: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. New Engl J Med 363:1693-1703, 2010
5. Shaw AT, Yeap BY, Solomon BJ, et al: Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: A retrospective analysis. Lancet Oncol 12:1004-1012, 2011
6. Camidge DR, Bang YJ, Kwak EL, et al: Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: Updated results from a phase 1 study. Lancet Oncol 13:1011-1019, 2012
7. Shaw AT, Kim DW, Nakagawa K, et al: Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. New Engl J Med 368:2385-2394, 2013
8. Djalalov S, Beca J, Hoch JS, et al: Cost effectiveness of EML4-ALK fusion testing and first-line crizotinib treatment for patients with advanced ALK-positive non-small-cell lung cancer. J Clin Oncol 32:1012-1019, 2014
9. Folland S, Goodman AC, Stano M: The Economics of Health and Health Care (ed 6). Boston, MA, Prentice Hall, 2010, pp 64-84
10. Lindeman NI, Cagle PT, Beasley MB, et al: Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol 8:823-859, 2013
11. Atherly AJ, Camidge DR: The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers. Br J Cancer 106:1100-1106, 2012
12. Hillner BE, Smith TJ: Efficacy does not necessarily translate to cost effectiveness: A case study in the challenges associated with 21st-century cancer drug pricing. J Clin Oncol 27:2111-2113, 2009
13. Hillner BE, Smith TJ: Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer: A decision-analysis model. New Engl J Med 324:160-168, 1991
14. Rawlins MD: NICE: Moving onward. New Engl J Med 369:3-5, 2013
15. Smith TJ, Hillner BE: Concrete options and ideas for increasing value in oncology care: The view from one trench. Oncologist 15:65-72, 2010 (suppl 1)
16. Kantarjian HM, Fojo T, Mathisen M, et al: Cancer drugs in the United States: Justum Pretium-The just price. J Clin Oncol 31:3600-3604, 2013